2,708 research outputs found
Recommended from our members
Mapping genetic interactions in cancer: a road to rational combination therapies.
The discovery of synthetic lethal interactions between poly (ADP-ribose) polymerase (PARP) inhibitors and BRCA genes, which are involved in homologous recombination, led to the approval of PARP inhibition as a monotherapy for patients with BRCA1/2-mutated breast or ovarian cancer. Studies following the initial observation of synthetic lethality demonstrated that the reach of PARP inhibitors is well beyond just BRCA1/2 mutants. Insights into the mechanisms of action of anticancer drugs are fundamental for the development of targeted monotherapies or rational combination treatments that will synergize to promote cancer cell death and overcome mechanisms of resistance. The development of targeted therapeutic agents is premised on mapping the physical and functional dependencies of mutated genes in cancer. An important part of this effort is the systematic screening of genetic interactions in a variety of cancer types. Until recently, genetic-interaction screens have relied either on the pairwise perturbations of two genes or on the perturbation of genes of interest combined with inhibition by commonly used anticancer drugs. Here, we summarize recent advances in mapping genetic interactions using targeted, genome-wide, and high-throughput genetic screens, and we discuss the therapeutic insights obtained through such screens. We further focus on factors that should be considered in order to develop a robust analysis pipeline. Finally, we discuss the integration of functional interaction data with orthogonal methods and suggest that such approaches will increase the reach of genetic-interaction screens for the development of rational combination therapies
Post-transcriptional knowledge in pathway analysis increases the accuracy of phenotypes classification
Motivation: Prediction of phenotypes from high-dimensional data is a crucial
task in precision biology and medicine. Many technologies employ genomic
biomarkers to characterize phenotypes. However, such elements are not
sufficient to explain the underlying biology. To improve this, pathway analysis
techniques have been proposed. Nevertheless, such methods have shown lack of
accuracy in phenotypes classification. Results: Here we propose a novel
methodology called MITHrIL (Mirna enrIched paTHway Impact anaLysis) for the
analysis of signaling pathways, which has built on top of the work of Tarca et
al., 2009. MITHrIL extends pathways by adding missing regulatory elements, such
as microRNAs, and their interactions with genes. The method takes as input the
expression values of genes and/or microRNAs and returns a list of pathways
sorted according to their deregulation degree, together with the corresponding
statistical significance (p-values). Our analysis shows that MITHrIL
outperforms its competitors even in the worst case. In addition, our method is
able to correctly classify sets of tumor samples drawn from TCGA. Availability:
MITHrIL is freely available at the following URL:
http://alpha.dmi.unict.it/mithril
Perturbation Detection Through Modeling of Gene Expression on a Latent Biological Pathway Network: A Bayesian hierarchical approach
Cellular response to a perturbation is the result of a dynamic system of
biological variables linked in a complex network. A major challenge in drug and
disease studies is identifying the key factors of a biological network that are
essential in determining the cell's fate.
Here our goal is the identification of perturbed pathways from
high-throughput gene expression data. We develop a three-level hierarchical
model, where (i) the first level captures the relationship between gene
expression and biological pathways using confirmatory factor analysis, (ii) the
second level models the behavior within an underlying network of pathways
induced by an unknown perturbation using a conditional autoregressive model,
and (iii) the third level is a spike-and-slab prior on the perturbations. We
then identify perturbations through posterior-based variable selection.
We illustrate our approach using gene transcription drug perturbation
profiles from the DREAM7 drug sensitivity predication challenge data set. Our
proposed method identified regulatory pathways that are known to play a
causative role and that were not readily resolved using gene set enrichment
analysis or exploratory factor models. Simulation results are presented
assessing the performance of this model relative to a network-free variant and
its robustness to inaccuracies in biological databases
Recommended from our members
DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity.
An individual malignant tumor is composed of a heterogeneous collection of single cells with distinct molecular and phenotypic features, a phenomenon termed intratumoral heterogeneity. Intratumoral heterogeneity poses challenges for cancer treatment, motivating the need for combination therapies. Single-cell technologies are now available to guide effective drug combinations by accounting for intratumoral heterogeneity through the analysis of the signaling perturbations of an individual tumor sample screened by a drug panel. In particular, Mass Cytometry Time-of-Flight (CyTOF) is a high-throughput single-cell technology that enables the simultaneous measurements of multiple ([Formula: see text]40) intracellular and surface markers at the level of single cells for hundreds of thousands of cells in a sample. We developed a computational framework, entitled Drug Nested Effects Models (DRUG-NEM), to analyze CyTOF single-drug perturbation data for the purpose of individualizing drug combinations. DRUG-NEM optimizes drug combinations by choosing the minimum number of drugs that produce the maximal desired intracellular effects based on nested effects modeling. We demonstrate the performance of DRUG-NEM using single-cell drug perturbation data from tumor cell lines and primary leukemia samples
Receptor Tyrosine Kinases Fall into Distinct Classes Based on Their Inferred Signaling Networks
Although many anticancer drugs that target receptor tyrosine kinases (RTKs) provide clinical benefit, their long-term use is limited by resistance that is often attributed to increased abundance or activation of another RTK that compensates for the inhibited receptor. To uncover common and unique features in the signaling networks of RTKs, we measured time-dependent signaling in six isogenic cell lines, each expressing a different RTK as downstream proteins were systematically perturbed by RNA interference. Network models inferred from the data revealed a conserved set of signaling pathways and RTK-specific features that grouped the RTKs into three distinct classes: (i) an EGFR/FGFR1/c-Met class constituting epidermal growth factor receptor, fibroblast growth factor receptor 1, and the hepatocyte growth factor receptor c-Met; (ii) an IGF-1R/NTRK2 class constituting insulin-like growth factor 1 receptor and neurotrophic tyrosine receptor kinase 2; and (iii) a PDGFRβ class constituting platelet-derived growth factor receptor β. Analysis of cancer cell line data showed that many RTKs of the same class were coexpressed and that increased abundance of an RTK or its cognate ligand frequently correlated with resistance to a drug targeting another RTK of the same class. In contrast, abundance of an RTK or ligand of one class generally did not affect sensitivity to a drug targeting an RTK of a different class. Thus, classifying RTKs by their inferred networks and then therapeutically targeting multiple receptors within a class may delay or prevent the onset of resistance.W. M. Keck FoundationNational Institutes of Health (U.S.) (R21 CA126720)National Institutes of Health (U.S.) (P50 GM068762)National Institutes of Health (U.S.) (RC1 HG005354)National Institutes of Health (U.S.) (U54-CA112967)National Institutes of Health (U.S.) (R01-CA096504)Alfred and Isabel Bader (Fellowship)Jacques-Emile Dubois (fellowship
Combining Network Modeling and Experimental Approaches to Predict Drug Combination Responses
Cancer is a lethal disease and complex at multiple levels of cell biology. Despite many advances in treatments, many patients do not respond to therapy. This is owing to the complexity of cancer-genetic variability due to mutations, the multi-variate biochemical networks within which drug targets reside and existence and plasticity of multiple cell states. It is generally understood that a combination of drugs is a way to address the multi-faceted drivers of cancer and drug resistance. However, the sheer number of testable combinations and challenges in matching patients to appropriate combination treatments are major issues.
Here, we first present a general method of network inference which can be applied to infer biological networks. We apply this method to infer different kinds of networks in biological levels where cancer complexity resides-a biochemical network, gene expression and cell state transitions. Next, we focus our attention on glioblastoma and with pharmacological and biological considerations, obtain a ranked list of important drug targets in glioblastoms. We perform drug dose response experiments for 22 blood brain barrier penetrant drugs against 3 glioblastoma cell lines. These methods and experimental results inform a construction of a temporal cell state model to predict and experimentally validate combination treatments for certain drugs. We improve an experimental method to perform high throughput western blots and apply the method to discover biochemical interactions among some important proteins involved in temporal cell state transitions. Lastly, we illustrate a method to investigate potential resistance mechanisms in genome scale proteomic data.
We hope that methods and results presented here can be adapted and improved upon to help in the discovery of biochemical interactions, capturing cell state transitions and ultimately help predict effective combination therapies for cancer
Bridging scales in cancer progression: Mapping genotype to phenotype using neural networks
In this review we summarize our recent efforts in trying to understand the
role of heterogeneity in cancer progression by using neural networks to
characterise different aspects of the mapping from a cancer cells genotype and
environment to its phenotype. Our central premise is that cancer is an evolving
system subject to mutation and selection, and the primary conduit for these
processes to occur is the cancer cell whose behaviour is regulated on multiple
biological scales. The selection pressure is mainly driven by the
microenvironment that the tumour is growing in and this acts directly upon the
cell phenotype. In turn, the phenotype is driven by the intracellular pathways
that are regulated by the genotype. Integrating all of these processes is a
massive undertaking and requires bridging many biological scales (i.e.
genotype, pathway, phenotype and environment) that we will only scratch the
surface of in this review. We will focus on models that use neural networks as
a means of connecting these different biological scales, since they allow us to
easily create heterogeneity for selection to act upon and importantly this
heterogeneity can be implemented at different biological scales. More
specifically, we consider three different neural networks that bridge different
aspects of these scales and the dialogue with the micro-environment, (i) the
impact of the micro-environment on evolutionary dynamics, (ii) the mapping from
genotype to phenotype under drug-induced perturbations and (iii) pathway
activity in both normal and cancer cells under different micro-environmental
conditions
Perturbation biology: inferring signaling networks in cellular systems.
We present a powerful experimental-computational technology for inferring network models that predict the response of cells to perturbations, and that may be useful in the design of combinatorial therapy against cancer. The experiments are systematic series of perturbations of cancer cell lines by targeted drugs, singly or in combination. The response to perturbation is quantified in terms of relative changes in the measured levels of proteins, phospho-proteins and cellular phenotypes such as viability. Computational network models are derived de novo, i.e., without prior knowledge of signaling pathways, and are based on simple non-linear differential equations. The prohibitively large solution space of all possible network models is explored efficiently using a probabilistic algorithm, Belief Propagation (BP), which is three orders of magnitude faster than standard Monte Carlo methods. Explicit executable models are derived for a set of perturbation experiments in SKMEL-133 melanoma cell lines, which are resistant to the therapeutically important inhibitor of RAF kinase. The resulting network models reproduce and extend known pathway biology. They empower potential discoveries of new molecular interactions and predict efficacious novel drug perturbations, such as the inhibition of PLK1, which is verified experimentally. This technology is suitable for application to larger systems in diverse areas of molecular biology
- …